Medeor Therapeutics Overview
- Year Founded
-
2012

- Status
-
Private
- Latest Deal Type
-
Debt - PPP
- Investors
-
7
Medeor Therapeutics General Information
Description
Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.
Contact Information
Website
www.medeortx.comCorporate Office
- 611 Gateway Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
Corporate Office
- 611 Gateway Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
Medeor Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Debt - PPP | 29-Apr-2020 | Completed | Generating Revenue | |||
5. Grant | 22-Jan-2018 | Completed | Generating Revenue | |||
4. Later Stage VC (Series B) | 27-Nov-2017 | Completed | Generating Revenue | |||
3. Early Stage VC (Series A) | 16-Oct-2015 | Completed | Generating Revenue | |||
2. Early Stage VC | 02-Oct-2013 | $1.55M | $2.55M | Completed | Generating Revenue | |
1. Seed Round | 11-Jan-2013 | $1M | $1M | Completed | Generating Revenue |
Medeor Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | ||||||||
Series A | ||||||||
Seed 1 | 1,291,667 | $0.000100 | 8% | $1.2 | $1.2 | 1x | $1.2 | 4.67% |
Seed | 1,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 3.61% |
Medeor Therapeutics Patents
Medeor Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240108655-A1 | Methods of producing mixed chimerism after a solid organ transplant | Pending | 13-Sep-2022 | ||
US-20230201256-A1 | Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient | Pending | 21-May-2020 | ||
US-20220305057-A1 | Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells | Pending | 06-Jun-2019 | ||
EP-3980036-A4 | Methods of making cellular products by post-mortem mobilization and harvesting of hematopoietic cells | Inactive | 06-Jun-2019 | ||
EP-3980036-A1 | Methods of making cellular products by post-mortem mobilization and harvesting of hematopoietic cells | Inactive | 06-Jun-2019 | A61K35/28 |
Medeor Therapeutics Investors (7)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
California Institute for Regenerative Medicine | Government | |||
120 Capital | Venture Capital | Minority | ||
6 Dimensions Capital | Venture Capital | Minority | ||
RA Capital Management | Venture Capital | Minority | ||
Sofinnova Investments | Venture Capital | Minority |
Medeor Therapeutics FAQs
-
When was Medeor Therapeutics founded?
Medeor Therapeutics was founded in 2012.
-
Where is Medeor Therapeutics headquartered?
Medeor Therapeutics is headquartered in South San Francisco, CA.
-
What industry is Medeor Therapeutics in?
Medeor Therapeutics’s primary industry is Biotechnology.
-
Is Medeor Therapeutics a private or public company?
Medeor Therapeutics is a Private company.
-
What is Medeor Therapeutics’s current revenue?
The current revenue for Medeor Therapeutics is
. -
How much funding has Medeor Therapeutics raised over time?
Medeor Therapeutics has raised $67.5M.
-
Who are Medeor Therapeutics’s investors?
California Institute for Regenerative Medicine, 120 Capital, 6 Dimensions Capital, RA Capital Management, and Sofinnova Investments are 5 of 7 investors who have invested in Medeor Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »